Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex
- PMID: 21175212
- PMCID: PMC3071873
- DOI: 10.1021/jm101359c
Interactions of monoamine oxidases with the antiepileptic drug zonisamide: specificity of inhibition and structure of the human monoamine oxidase B complex
Abstract
The binding of zonisamide to purified, recombinant monoamine oxidases (MAOs) has been investigated. It is a competitive inhibitor of human MAO B (K(i) = 3.1 ± 0.3 μM), of rat MAO B (K(i) = 2.9 ± 0.5 μM), and of zebrafish MAO (K(i) = 30.8 ± 5.3 μM). No inhibition is observed with purified human or rat MAO A. The 1.8 Å structure of the MAO B complex demonstrates that it binds within the substrate cavity.
Figures




References
-
- Uno H, Kuokawa M, Masuda Y, Nishimara H. Studies on 3- substituted 1,2-benzisoxazole derivatives, 6. Synthesis of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem. 1979;22:180–183. - PubMed
-
- Murata M. Novel Therapeutic Effects of the Anti-convulsant, Zonisamide, on Parkinson's Disease. Curr. Pharm. Des. 2004;10:687–693. - PubMed
-
- Yang LPH, Perry CM. Zonisamide in Parkinson's Disease. CNS Drugs. 2009;23:703–711. - PubMed
-
- Okada M, Kaneko S, Hirano T, Mizuno K, Kondo , Otani K, Fukushima Y. Effects of Zonisamide on Dopamminergic System. Epilepsy Res. 1995;22:193–205. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources